(Q33777342)

29 July 2017

1 reference

title

Antiarrhythmic agents for atrial fibrillation: focus on prolonging atrial repolarization (English)

1 reference

29 July 2017

1 reference

Singh BN

1

1 reference

29 July 2017

Mody FV

series ordinal

2

1 reference

29 July 2017

Lopez B

series ordinal

3

1 reference

29 July 2017

Sarma JS

series ordinal

4

1 reference

29 July 2017

language of work or name

English

0 references

publication date

1 November 1999

1 reference

American Journal of Cardiology

29 July 2017

published in

1 reference

29 July 2017

volume

84

1 reference

29 July 2017

issue

9A

1 reference

29 July 2017

page(s)

161R-173R

1 reference

Controlling cardiac arrhythmias: an overview with a historical perspective

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900718-3

Antiarrhythmic therapy--future trends and forecast for the 21st century

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900718-3

An overview of arrhythmias and antiarrhythmic approaches

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900718-3

The seventh annual Gordon K. Moe Lecture. Atrial fibrillation: from cell t bedside

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900718-3

A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900718-3

Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900718-3

Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900718-3

Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900718-3

Atrial fibrillation: maintaining stability of sinus rhythm or ventricular rate control? The need for prospective data: the PIAF trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900718-3

Beneficial effects of low dose amiodarone in patients with congestive cardiac failure: a placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900718-3

Left ventricular dysfunction due to atrial fibrillation in patients initially believed to have idiopathic dilated cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900718-3

Pulsed Doppler evaluation of atrial mechanical function after electrical cardioversion of atrial fibrillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900718-3

Current antiarrhythmic drugs: an overview of mechanisms of action and potential clinical utility

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900718-3

Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900718-3

Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900718-3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900718-3

Effects of flecainide and quinidine on human atrial action potentials. Role of rate-dependence and comparison with guinea pig, rabbit, and dog tissues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900718-3

Control of cardiac arrhythmias by selective lengthening of repolarization: theoretic considerations and clinical observations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900718-3

A third class of anti-arrhythmic action. Effects on atrial and ventricular intracellular potentials, and other pharmacological actions on cardiac muscle, of MJ 1999 and AH 3474

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900718-3

The effect of amiodarone, a new anti-anginal drug, on cardiac muscle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900718-3

What should we expect from the next generation of antiarrhythmic drugs?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900718-3

Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Ibutilide Repeat Dose Study Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900718-3

Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. Intravenous Dofetilide Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900718-3

Ibutilide and the treatment of atrial arrhythmias. A new drug--almost unheralded--is now available to US physicians

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900718-3

Facilitating transthoracic cardioversion of atrial fibrillation with ibutilide pretreatment.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900718-3

Clinical relevance of cardiac arrhythmias generated by afterdepolarizations. Role of M cells in the generation of U waves, triggered activity and torsade de pointes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900718-3

Amiodarone-associated proarrhythmic effects. A review with special reference to torsade de pointes tachycardia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900718-3

Antiarrhythmic actions of amiodarone: a profile of a paradoxical agent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900718-3

Cellular electropharmacology of amiodarone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900718-3

Expanding indications for the use of Class III agents in patients at high risk for sudden death

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900718-3

Low-dose amiodarone versus sotalol for suppression of recurrent symptomatic atrial fibrillation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900718-3

The coming of age of the class III antiarrhythmic principle: retrospective and future trends

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900718-3

Antiarrhythmic drugs: a reorientation in light of recent developments in the control of disorders of rhythm

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900718-3

Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900718-3

Efficacy of sotalol in controlling reentrant supraventricular tachycardias.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900718-3

Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900718-3

Comparisons of oral propafenone and sotalol as an initial treatment in patients with symptomatic paroxysmal atrial fibrillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900718-3

Multicenter comparative study of the efficacy and safety of sotalol in the prophylactic treatment of patients with paroxysmal supraventricular tachyarrhythmias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900718-3

Maintenance of sinus rhythm with oral d,l-sotalol therapy in patients with symptomatic atrial fibrillation and/or atrial flutter. d,l-Sotalol Atrial Fibrillation/Flutter Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900718-3

Significance and Prevention of Atrial Fibrillation Occurring After Cardiac Surgery: A Time for Fundamental Change in Strategy?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900718-3

Effectiveness of sotalol in preventing supraventricular tachyarrhythmias shortly after coronary artery bypass grafting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900718-3

Selective versus non-selective antiarrhythmic approach for prevention of atrial fibrillation after coronary surgery: is there a need for pre-operative risk stratification? A prospective placebo-controlled study using low-dose sotalol.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900718-3

Chronic amiodarone reduces transmural dispersion of repolarization in the canine heart

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900718-3

Barium-induced nondriven action potentials as a model of triggered potentials from early afterdepolarizations: significance of slow channel activity and differing effects of quinidine and amiodarone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900718-3

Amiodarone for maintenance of sinus rhythm after conversion of atrial fibrillation in the setting of a dilated left atrium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900718-3

Amiodarone for refractory atrial fibrillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900718-3

Efficacy of amiodarone for refractory supraventricular tachyarrhythmias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900718-3

Use of amiodarone in the treatment of persistent and paroxysmal atrial fibrillation resistant to quinidine therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900718-3

Amiodarone in the management of refractory atrial fibrillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900718-3

Low-dose amiodarone for atrial fibrillation: time for a prospective study?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900718-3

Low-dose amiodarone for atrial fibrillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900718-3

Effectiveness of amiodarone and electrical cardioversion for chronic rheumatic atrial fibrillation after mitral valve surgery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900718-3

Long-term efficacy of amiodarone for the maintenance of normal sinus rhythm in patients with refractory atrial fibrillation or flutter.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900718-3

Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900718-3

Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the veterans affairs congestive heart failure survival trial of antiarrhythmic therapy (CHF-STAT). The Dep

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900718-3

Frequency-dependent Cardiac Electrophysiologic Effects of Tedisamil: Comparison With Quinidine and Sotalol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900718-3

Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900718-3

Azimilide dihydrochloride, a novel antiarrhythmic agent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900718-3

The azimilide post-infarct survival evaluation (ALIVE) trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900718-3

Impact of managed care on the treatment of atrial fibrillation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900718-3

Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover open-label study of five drug regimens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900718-3

Serial antiarrhythmic drug treatment to maintain sinus rhythm after electrical cardioversion for chronic atrial fibrillation or atrial flutter

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900718-3

10.1016/S0002-9149(99)00718-3

7 January 2021

Identifiers

DOI

1 reference

29 July 2017

1 reference